Quince Therapeutics Statistics
Total Valuation
QNCX has a market cap or net worth of $16.85 million. The enterprise value is -$906,715.
| Market Cap | 16.85M |
| Enterprise Value | -906,715 |
Important Dates
The next estimated earnings date is Monday, August 10, 2026, after market close.
| Earnings Date | Aug 10, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
QNCX has 977,962 shares outstanding. The number of shares has increased by 42.34% in one year.
| Current Share Class | 977,962 |
| Shares Outstanding | 977,962 |
| Shares Change (YoY) | +42.34% |
| Shares Change (QoQ) | +65.04% |
| Owned by Insiders (%) | 3.03% |
| Owned by Institutions (%) | 6.89% |
| Float | 878,174 |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.76 |
| P/TBV Ratio | 1.08 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.92, with a Debt / Equity ratio of 0.03.
| Current Ratio | 2.92 |
| Quick Ratio | 2.82 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -53.18 |
Financial Efficiency
Return on equity (ROE) is -192.90% and return on invested capital (ROIC) is -120.53%.
| Return on Equity (ROE) | -192.90% |
| Return on Assets (ROA) | -45.44% |
| Return on Invested Capital (ROIC) | -120.53% |
| Return on Capital Employed (ROCE) | -272.23% |
| Weighted Average Cost of Capital (WACC) | 15.86% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$951,447 |
| Employee Count | 38 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -2.17M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -94.33% in the last 52 weeks. The beta is 1.40, so QNCX's price volatility has been higher than the market average.
| Beta (5Y) | 1.40 |
| 52-Week Price Change | -94.33% |
| 50-Day Moving Average | 21.92 |
| 200-Day Moving Average | 247.31 |
| Relative Strength Index (RSI) | 36.59 |
| Average Volume (20 Days) | 29,786 |
Short Selling Information
| Short Interest | 2.01M |
| Short Previous Month | 2.06M |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 1.04 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -48.61M |
| Pretax Income | -35.21M |
| Net Income | -36.16M |
| EBITDA | -48.46M |
| EBIT | -48.61M |
| Earnings Per Share (EPS) | -$137.27 |
Balance Sheet
The company has $18.16 million in cash and $406,000 in debt, with a net cash position of $17.76 million or $18.16 per share.
| Cash & Cash Equivalents | 18.16M |
| Total Debt | 406,000 |
| Net Cash | 17.76M |
| Net Cash Per Share | $18.16 |
| Equity (Book Value) | 15.67M |
| Book Value Per Share | 22.73 |
| Working Capital | 16.81M |
Cash Flow
In the last 12 months, operating cash flow was -$39.45 million and capital expenditures -$204,000, giving a free cash flow of -$39.66 million.
| Operating Cash Flow | -39.45M |
| Capital Expenditures | -204,000 |
| Depreciation & Amortization | 146,000 |
| Net Borrowing | -5.55M |
| Free Cash Flow | -39.66M |
| FCF Per Share | -$40.55 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
QNCX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -42.34% |
| Shareholder Yield | -42.34% |
| Earnings Yield | -214.57% |
| FCF Yield | -235.34% |
Analyst Forecast
The average price target for QNCX is $86.67, which is 403.02% higher than the current price. The consensus rating is "Buy".
| Price Target | $86.67 |
| Price Target Difference | 403.02% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on June 30, 2026. It was a reverse split with a ratio of 1:20.
| Last Split Date | Jun 30, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |